

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

210296Orig1s000

OTHER ACTION LETTERS



NDA 210296

TENTATIVE APPROVAL

Banner Life Sciences, LLC
Attention: Thomas Lategan, PhD
Vice President, Regulatory Affairs
4125 Premier Drive
High Point, NC 27265

Dear Dr. Lategan:

Please refer to your New Drug Application (NDA), dated and received January 18, 2018, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Bafiertam (monomethyl fumarate) delayed-release capsule, 95 mg.

This NDA provides for the use of Bafiertam (monomethyl fumarate) delayed-release capsule, 95 mg, for the treatment of adult patients with relapsing forms of multiple sclerosis.

We have completed our review of this application, as amended. It is tentatively approved under 21 CFR 314.105 for use as recommended in the agreed-upon enclosed labeling (text for the Prescribing Information, Patient Package Insert, carton and container labels). This determination is based upon information available to the Agency at this time, [i.e., information in your application and the status of current good manufacturing practices (cGMPs) of the facilities used in the manufacture and testing of the drug product]. This determination is subject to change on the basis of any new information that may come to our attention.

The listed drug upon which your application relies is subject to a period of patent and/or exclusivity protection, and therefore, final approval of your application under section 505(c)(3) of the Act [21 U.S.C. 355(c)(3)] may not be made effective until the period has expired.

To obtain final approval of this application, submit an amendment two or six months prior to the: 1) expiration of the patents or 2) date you believe that your NDA will be eligible for final approval, as appropriate. In your cover letter, clearly identify your amendment as **“REQUEST FOR FINAL APPROVAL”**. This amendment should provide the legal/regulatory basis for your request for final approval and should include a copy of any relevant court order or judgment settlement, or licensing agreement, as appropriate. In addition to a safety update, the amendment should also identify changes, if any, in the conditions under which your product was tentatively approved, i.e., updated labeling; chemistry, manufacturing, and controls data. If there are no changes, clearly state so in your cover letter. Your amendment should include labeling, either identical to the enclosed or with changes marked. Any changes require our review before final approval and the goal date for our review will be set accordingly.

Until we issue a final approval letter, this NDA is not deemed approved.

Please note that this drug product may not be marketed in the United States without final agency approval under Section 505 of the Act. The introduction or delivery for introduction into interstate commerce of this drug product before the final approval date is prohibited under Section 501 of the Act and 21 U.S.C. 331(d).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We note that if this application is ultimately approved, you will need to meet these requirements.

ADDITIONAL COMMENTS

Office of Pharmaceutical Quality

We note your November 16, 2018, agreement, via electronic communication, to include the following changes in your amendment, which requests final approval of your application:

1. Revise Section P.8.1 to reflect the assigned 24-month shelf life at refrigerated conditions (5°C), with an in-use storage condition of USP controlled room temperature for 3 months.
2. Revise the specification tables in stability Section P.8.3 (document PD17-064A), and section P.8.2 (documents PD16-330B and PD16-332A) to include the revised limits for individual and total impurities. We acknowledge that you have amended the total impurity specification from (b) (4) % consistent with the revised limits.
3. Revise Section P.8.2 to reflect the agreement that requests for shelf-life extension will be submitted as prior approval supplements if based on statistical extrapolation of data, or CBE-30 supplements if based on real-time data. See Quality Amendment supporting document 21 dated October 10, 2018.

If you have any questions, call Sandra Folkendt, Regulatory Project Manager, at (240) 402-2804.

Sincerely,

{See appended electronic signature page}

Eric Bastings, MD
Deputy Director
Division of Neurology Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURES:

Content of Labeling
Prescribing Information
Patient Package Insert
Carton and Container Labeling

25 Page(s) of Draft Labeling have been Withheld in Full as B4 (CCI/TS)
immediately following this page

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

ERIC P BASTINGS
11/16/2018